Alterity Therapeutics (ATHE) Share-based Compensation (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Share-based Compensation of -$7875.5 for Q2 2020, down 112.61% year-over-year from $62438.7 in Q3 2019, and down 112.61% quarter-over-quarter from $62438.7 in Q2 2019.
Alterity Therapeutics (ATHE) Share-based Compensation (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at -$7875.5 for Q2 2020.
- In Q2 2020, Share-based Compensation fell 112.61% year-over-year to -$7875.5; the TTM figure through Jun 2020 stood at $3611.4 (up 103.18% YoY), while the FY2025 annual figure was $627573.3, up 7.97% from the prior year.
- Share-based Compensation for Q2 2020 stood at -$7875.5, down from $62438.7 in the prior quarter.
- The five-year high for Share-based Compensation was $62438.7 in Q2 2019, with the low at -$124886.5 in Q4 2017.
- The 4-year median for Share-based Compensation is -$1043.8 (2020), against an average of -$17150.1.
- The sharpest annual moves came in 2019 and 2020: Share-based Compensation soared 978.79% in 2019, then slumped 112.61% in 2020.
- Alterity Therapeutics' Share-based Compensation stood at -$124886.5 in 2017, then jumped by 54.57% to -$56739.6 in 2018, then soared by 210.04% to $62438.7 in 2019, then sank by 112.61% to -$7875.5 in 2020.
- Business Quant data shows ATHE's Share-based Compensation at -$7875.5 in Q2 2020, $62438.7 in Q2 2019, and -$56739.6 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Alterity Therapeutics | 50.14 Mn | 17.84 Mn | - | -2.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.45 Mn |
| Dec 31, 2025 | -1.45 Mn |
| Dec 31, 2024 | -519,710.43 |
| Dec 31, 2024 | -519,710.43 |
| Jun 30, 2024 | 581.23 Bn |
| Jun 30, 2024 | 581.23 Bn |
| Dec 31, 2023 | -203,295.86 |
| Dec 31, 2023 | -203,295.86 |
| Jun 30, 2023 | 646.02 Bn |
| Jun 30, 2023 | 646.02 Bn |
| Dec 31, 2022 | -412,099.19 |
| Dec 31, 2022 | -412,099.19 |
| Jun 30, 2022 | 1,078.79 Bn |
| Jun 30, 2022 | 1,078.79 Bn |
| Dec 31, 2021 | -637,659.61 |
| Dec 31, 2021 | -637,659.61 |
| Jun 30, 2021 | 1,451.37 Bn |
| Jun 30, 2021 | 1,451.37 Bn |
| Dec 31, 2020 | -1.15 Mn |
| Dec 31, 2020 | -1.15 Mn |